Addressing endocrine resistance in hormone receptor-positive breast cancer, Padrão et al. identify the glucocorticoid receptor (GR) as the key transducer of fasting benefits. They demonstrate that pharmacological GR activation recapitulates antitumor efficacy, offering a targeted therapeutic avenue that avoids the challenges of rigorous dieting.
Glucocorticoids mediate fasting efficacy in breast cancer.
TL;DR
Addressing endocrine resistance in hormone receptor-positive breast cancer, Padrão et al. identify the glucocorticoid receptor (GR) as the key transducer of fasting benefits. They demonstrate that pharmacological GR activation recapitulates antitumor efficacy, offering a targeted therapeutic avenue that avoids the challenges of rigorous dieting.
Credibility Assessment
Preliminary — 38/100
Study Design
Rigor of the research methodology
5/20
Sample Size
Whether the study was sufficiently powered
7/20
Peer Review
Review status and journal reputation
10/20
Replication
Has this finding been independently reproduced?
6/20
Transparency
Funding disclosure and data availability
10/20
Overall
Sum of all five dimensions
38/100
0 Comments
Log in to join the discussion.